TP53 is altered in 9.89% of medulloblastoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

TP53 is altered in 50.0% of medulloepithelioma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

TP53 is altered in 23.53% of large cell/anaplastic medulloblastoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

TP53 is altered in 10.32% of central nervous system embryonal neoplasm patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

TP53 is altered in 5.0% of desmoplastic/nodular medulloblastoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain TP53 Mutation (somatic) and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

TP53 is altered in 87.33% of esophageal squamous cell carcinoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 79.98% of esophageal adenocarcinoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 70.7% of adenocarcinoma of the gastroesophageal junction patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 66.31% of anaplastic astrocytoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 53.66% of gastric adenocarcinoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 43.14% of diffuse midline glioma, H3 K27M-mutant patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 39.21% of malignant glioma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 37.92% of diffuse glioma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 36.79% of glioblastoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 38.12% of high-grade glioma, NOS patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 12.78% of anaplastic oligodendroglioma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 9.52% of anaplastic ependymoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 18.18% of anaplastic pleomorphic xanthoastrocytoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 is altered in 2.56% of ependymoma patients [4].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

TP53 Mutation (somatic) is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 Mutation (somatic) and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].